MEET THE CORE: SUSAN BRENNER-MORTON

MEET THE CORE: SUSAN BRENNER-MORTON Susan Brenner-Morton is an antibody expert who has spent decades developing these specialized tools to help us understand how motor neurons function normally—and dysfunction in ALS. We sat down virtually with Susan, who is Director …
/ Read More

Prosetin Receives Orphan Drug Designation

Earlier this month, we reached a big regulatory milestone: Prosetin received Orphan Drug Designation, or orphan status, for the treatment of ALS from the Food and Drug Administration (FDA). Here, we break down what orphan status means, why it’s important, …
/ Read More
ALS Research Lab

Improving Pharmacokinetic Properties of Promising Compounds

In our biweekly webinars, we have described the process of developing Prosetin—the first potential investigational drug to emerge from The Project ALS Therapeutics Core at Columbia (THE CORE)—in detail. A collaborative team led by Drs. Emily Lowry, Pieter Bos, Brent …
/ Read More
The Wasserman Family

One Family’s Passionate Fight Against Neurodegenerative Diseases

The Wasserman family has experienced first-hand the devastating effects of neurodegenerative diseases: Sandra Wasserman lost her beloved husband to Parkinson’s disease, and her son to glioblastoma. Now in her eighties, Sandra has friends experiencing the debilitating consequences of Alzheimer’s disease …
/ Read More

COVID-19 UPDATE FROM THE CORE

Last year, Project ALS launched The Project ALS Therapeutics Core at Columbia (THE CORE), a 3-year, $6.3M initiative toward the first meaningful therapies for ALS. Led by scientific co-directors Hynek Wichterle, PhD, Neil Shneider, MD, PhD, and Serge Przedborski, MD, …
/ Read More

A COVID-19 Research Update

Dear Friends, Project ALS is acutely aware of the unimaginable circumstances that Americans and people around the world are now facing. Our hearts, souls, and minds are heavy with the dire situation that ALS patients, family members, and loved ones …
/ Read More

Valentine for a Pioneer

“Jaci is blazing a path that hopefully will not just cure her but set a course of treatment for countless others.” – Lori Hermstad, mother. February 14th is a significant day for the Hermstad family. On this day in 2011, …
/ Read More

Project ALS Introduces Prosetin

What’s Prosetin? If you’ve been following Project ALS, you have probably heard us mention PHB, our working name for The Core’s first drug candidate-in-development. Now, we are proud to announce the final version of PHB—the real thing—an investigational drug for …
/ Read More

Ai Yamamoto Joins Research Advisory Board

Project ALS is thrilled to welcome Dr. Ai Yamamoto to the Research Advisory Board and recognizes her leadership as she is joining our decision-making body. Dr. Yamamoto is the Associate Professor of Neurology and Pathology and Cell Biology at Columbia …
/ Read More